Which medication is commonly used to increase fetal hemoglobin production in sickle cell disease, reducing vaso-occlusive events?

Which medication is commonly used to increase fetal hemoglobin production in sickle cell disease, reducing vaso-occlusive events?

• A. Hydroxyurea
• B. Folic Acid
• C. Iron
• D. Vitamin C

Answer: (A)

Increasing fetal hemoglobin production is a key strategy in reducing sickling, because HbF inhibits the polymerization of hemoglobin S and thereby decreases red cell sickling and vaso-occlusive events. Hydroxyurea is the medication that reliably raises HbF levels in many patients with sickle cell disease. By boosting HbF, it reduces frequency of pain crises, acute chest syndrome, and hospitalizations, and it also has anti-inflammatory effects that help lessen vaso-occlusion. In practice, it is started at a low dose and titrated to the maximum tolerated dose, with regular blood monitoring due to potential myelosuppression. Folic acid supports red blood cell production but does not increase HbF. Iron therapy helps only if there is iron deficiency and does not raise HbF. Vitamin C is not used to enhance HbF and has no specific role in reducing vaso-occlusive crises. So, the option that best increases HbF and lowers vaso-occlusion is hydroxyurea.

Increasing fetal hemoglobin production is a key strategy in reducing sickling, because HbF inhibits the polymerization of hemoglobin S and thereby decreases red cell sickling and vaso-occlusive events.

Hydroxyurea is the medication that reliably raises HbF levels in many patients with sickle cell disease. By boosting HbF, it reduces frequency of pain crises, acute chest syndrome, and hospitalizations, and it also has anti-inflammatory effects that help lessen vaso-occlusion. In practice, it is started at a low dose and titrated to the maximum tolerated dose, with regular blood monitoring due to potential myelosuppression.

Folic acid supports red blood cell production but does not increase HbF. Iron therapy helps only if there is iron deficiency and does not raise HbF. Vitamin C is not used to enhance HbF and has no specific role in reducing vaso-occlusive crises.

So, the option that best increases HbF and lowers vaso-occlusion is hydroxyurea.